Vertex and the U.K.’s National Health Service could be closing in on a price deal for the drugmaker’s cystic fibrosis drugs.
According to a pharmaphorum report, representatives from Vertex and NHS are meeting soon to resolve a long-standing conflict of the price of the new CF drugs in the U.K.
Officials are looking to sit down with Vertex following an online petition calling for the availability of Vertex’s CF drugs. The petition garnered roughly 116,000 signatures.
Junior health ministers Steve Brine and Lord O’Shaughnessy in a letter to Vortex hoped for “urgent resolution” to the pricing conflict.
“We appreciate that these are difficult issues, but the counter-offer from NHS England to your last proposal was an important demonstration of its significant commitment to taking a collaborative and flexible approach in any discussions with you if you can commit to pricing that is responsible and proportionate to the benefits patients receive,” the letter says.
